Skip to content
18 November · 06:30 UTCFollow GSK by emailFollow

GSK · Pharma and healthcare · one day

GSK (GSK): news on Tuesday 17 November 2026

News from the 24 hours to Tuesday morning, 17 November 2026.

Tone of the day

+5.7positive
Relevant headlines8of 12 read
Stories5grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage leaned positive, driven by a European regulator committee backing wider use of ViiV's HIV drugs, a licensing deal and a broker raising its long-term revenue forecast. A favourable patent ruling and a modest share price gain added support, though some commentary was neutral.

What drove it

  • EMA HIV drug recommendation
  • Berenberg forecast upgrade
  • licensing and patent news

Around this day

DayToneHeadlines
Wed 11 Nov+4.56
Thu 12 Nov+4.512
Fri 13 Nov+4.214
Sat 14 Nov+9.220
Sun 15 Nov+7.06
Mon 16 Nov+2.54
Tue 17 Nov+5.78
Wed 18 Nov+7.536

5 stories · 8 headlines · strongest first

Pharma and healthcare on 17 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
GSK share outlook and market commentary +0.54 headlines today · 7 in all · Pieces discuss GSK's share price moves, support levels and long-term prospects.
+5.0Shares rose during the session.Traders Union (opens the article) ↗
+2.5Investor-focused overview with mildly constructive tone for long-term holders.}Yahoo Finance (opens the article) ↗
+2.0Technical price level discussion with steady cash flow noted.Traders Union (opens the article) ↗
0.0Speculative market outlook piece without concrete developments.Kalkine Media (opens the article) ↗
EMA committee backs wider use of ViiV HIV drugs +9.21 headline today · ViiV Healthcare received a committee recommendation to expand the use of its HIV drugs.
+9.2European regulator panel backed wider use of its HIV medicines.MarketScreener (opens the article) ↗
Berenberg raises GSK 2031 revenue forecast +7.51 headline today · Berenberg increased its 2031 revenue forecast for GSK.
+7.5Broker lifted long-range sales estimate, a positive view of prospects.AD HOC NEWS (opens the article) ↗
GSK weekly recap on licensing deal and cancer drugs +6.71 headline today · A weekly recap covers a GSK licensing deal and wider cancer drug coverage.
+6.7Recap highlights a licensing agreement and broader cancer drug coverage.TradingView (opens the article) ↗
GSK wins UPC injunction against Pfizer and BioNTech +7.61 headline today · 10 in all, since 12 November · A piece discusses the patent ruling's implications for GSK's licensing leverage.
+3.7Favourable patent decision strengthens licensing position despite small share dip.AD HOC NEWS (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt